Chemotherapy Compounding Labelling 
epicur
MARCH 12, 2024
Epicur Pharma’s Advisory Council member Ann Donoghue, DVM, MS shares her personal perspective on the important relationship between veterinary oncology and compounded medications used in chemotherapy treatments. Many of the presentations discussed the chemotherapies available to treat dogs.
European Pharmaceutical Review
OCTOBER 19, 2023
With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy? What do you envision the future of radiopharmaceuticals to be like?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 5, 2022
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
epicur
SEPTEMBER 13, 2023
However, the more closely we look at what it takes to compound an exact strength, the clearer it becomes standard dosages are more beneficial to both patients and veterinary practices. Exact strengths are compounded by a technician in capsules or tablets at traditional 503A pharmacies. milligram tablet and a 1.6 milligram tablet.
European Pharmaceutical Review
JULY 5, 2022
The availability of oral chemotherapy treatments would provide stomach cancer patients with the option of more efficacious drugs with improved tolerability in a more convenient dosage format” The poor clinical outcomes of stomach cancer make it a key target for drug development. Benefits of daily oral chemotherapy over IV.
Pharmaceutical Technology
MARCH 23, 2023
It is also being assessed in other tumour types and along with other Incyte pipeline compounds. Zynyz monotherapy showed a 52% objective response rate (ORR) in chemotherapy-naïve patients. We continue to study the potential of Zynyz in additional tumour types and in combination with other Incyte pipeline compounds.”
European Pharmaceutical Review
DECEMBER 5, 2022
PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto is an intravenous radioligand therapy that combines a ligand, a targeting compound with lutetium-177, a therapeutic radionuclide.
Expert insights. Personalized for you.
52 
Let's personalize your content